Alaric DeArment

Reporter at Scrip

Featured in: Favicon

informa.com (+3) Favicon

forbes.com Favicon

medium.com Favicon

nydailynews.com Favicon

sun-sentinel.com Favicon

newrepublic.com Favicon

abovethelaw.com Favicon

medcitynews.com Favicon

geneticliteracyproject.org Favicon

dealbreaker.com + 6 more

Articles

US FDA Expands Label For BMS’s Camzyos Days After Phase III Stumble

1 week ago | insights.citeline.com | Alaric DeArment

US FDA Expands Label For BMS’s Camzyos Days After Phase III StumbleThe agency loosened requirements for echocardiograms and removed contraindications for a number of commonly used drugs.
Lilly Scores With Orforglipron In Diabetes, Generating Excitement For Obesity

1 week ago | insights.citeline.com | Alaric DeArment

Lilly Scores With Orforglipron In Diabetes, Generating Excitement For ObesityThe company announced positive topline results for the oral GLP-1 drug in type 2 diabetes that beat expectations.
Telix Moves TLX101 Forward On Encouraging Early Brain Cancer Data

1 week ago | insights.citeline.com | Alaric DeArment

Telix Moves TLX101 Forward On Encouraging Early Brain Cancer DataThe company is planning to start a registrational program on its home turf in Australia and is planning to bring the therapy to the US as well.
Camzyos nHCM Failure Could Open Door To Threat From Cytokinetics’ Aficamten

1 week ago | insights.citeline.com | Alaric DeArment

Camzyos nHCM Failure Could Open Door To Threat From Cytokinetics’ AficamtenBMS’s Phase III ODYSSEY-HCM study did not show statistical significance for either of its two primary endpoints.
Verve Moves Toward Lilly Opt-In For PCSK9 Program With Phase Ib Results

1 week ago | insights.citeline.com | Alaric DeArment

Verve Moves Toward Lilly Opt-In For PCSK9 Program With Phase Ib ResultsThe company posted positive initial results from the Heart-2 trial in HeFH and CAD, with strong LDL cholesterol lowering and a clean safety profile.
J&J’s Icotrokinra Scores In Important Adolescent Patient Segment

1 week ago | insights.citeline.com | Alaric DeArment

J&J’s Icotrokinra Scores In Important Adolescent Patient SegmentThe company presented positive Phase III data from a subset analysis of ICONIC-LEAD comprising patients with moderate-to-severe plaque psoriasis.
Compounding Unlikely To Solve GLP-1 Affordable Access Issues

2 weeks ago | insights.citeline.com | Alaric DeArment

Compounding Unlikely To Solve GLP-1 Affordable Access Issues The end of semaglutide and tirzepatide shortages means large-scale compounding is declining, ICER noted. But compounded versions – and the demand for them – are likely here to stay.
Multiple Tactics Likely Needed To Control Obesity Drug Costs

2 weeks ago | insights.citeline.com | Alaric DeArment

Multiple Tactics Likely Needed To Control Obesity Drug CostsICER’s new white paper pointed to estimates that the GLP-1 drugs may result in more than $100bn in annual spending, highlighting the need to rein in costs.
Cartesian Maps Out CAR-T Strategy With Simpler Logistics In Mind

2 weeks ago | insights.citeline.com | Alaric DeArment

Cartesian Maps Out CAR-T Strategy With Simpler Logistics In MindThe company announced positive Phase IIb data for Descartes-08 in myasthenia gravis, with especially strong efficacy among patients without prior biologic treatment.
Rhythm Anticipates Smooth Sailing For Setmelanotide After Phase III Success

2 weeks ago | insights.citeline.com | Alaric DeArment

Rhythm Anticipates Smooth Sailing For Setmelanotide After Phase III SuccessThe company plans a tiered sales approach as it targets endocrinologists for hypothalamic obesity, which is more widely diagnosed than its current indication for Bardet-Biedl syndrome.